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Background. The aim of the study was to determine the secondary preventive medical supply of patients with peripheral arterial
disease(PAD)inGermanprimarycare.MethodsandResults.Apopulation-basedcasecontrolstudywasconductedusingelectronic
medical records of patients extracted from the CONTENT primary care database of Heidelberg, Germany, between April 2007 and
March 2010. The prescription rates of cardiovascular medication among symptomatic PAD patients were analysed by means of
the ATC classiﬁcation and compared with those of patients with cardiovascular disease (CVD). 479 cases with PAD and 958 sex-
and age-matched control CVD patients were identiﬁed. PAD patients showed signiﬁcantly lower prescription rates for cardiac
agents (21.7% versus 37%), β-blockers (50.1% versus. 66.2%), and lipid-lowering agents (50.3% versus 55.9%) compared to
CVD patients. In contrast, signiﬁcantly more prescriptions of antidiabetic agents (28.2% versus 20.3%), particularly insulin
and analogues (12.5% versus 8%), and calcium channel blockers (29.2% versus 24.3%) were found in PAD patients. Low-dose
aspirin use among both PAD and CVD patients was underestimated, as it is available without a prescription. Conclusions.O p t i m a l
pharmacotherapeutical care of patients with PAD requires more intensive cardioprotective medication in primary care settings.
1.Introduction
Pharmacotherapy in patients with peripheral arterial disease
(PAD) aims to prevent progression of atherosclerotic disease,
to reduce risk of global cardiovascular events and to improve
walking capacity. Since PAD is a manifestation of systemic
atherosclerosis in the lower extremities, its pharmacothera-
peutic goals are nearly identical to those of the cerebrovas-
cular disease and cardiovascular disease (CVD). Smoking
cessation, exercise, and an aggressive pharmacological risk
factor modiﬁcation, including diabetes, hypertension, lipid
abnormalities, and life-long antiplatelet therapy, represent
the cornerstones of treatment. The therapeutical recom-
mendations based on solid research are included in current
national and international PAD guidelines. Despite strict
guideline directives, the PAD is still considered today as
undertreated in many countries [1–4]. In particular, an
underuse of PAD treatment has been documented compared
to treatment of CVD patients [5–8].
In Germany, high prescription rates for secondary pre-
ventive medication in PAD patients primarily treated by
vascular specialists were recently reported [9]. The objectives
of the study were to examine whether an accordingly
intensive pharmacological PAD patient treatment is also
realized in primary care, particularly when compared with
those of CVD patients.
2. Methods
2.1. Data Source. The CONTENT (CONTinuous morbidity
registration Epidemiologic NETwork) database is a national
primary care research project which is created and main-
tained by the Department of General Practice and Health
Services Research of the University Hospital Heidelberg.
The structure and core elements of this datapool have been
described elsewhere [10]. In brief, based on the International
Classiﬁcation of Primary Care (ICPC-2) [11], all electronic,
routinely documented elements of doctor-patient encoun-
ters in 34 primary care settings in Southwest Germany are2 International Journal of Vascular Medicine
registered continuously and are available for analysis of
speciﬁc problem areas. The study protocol was approved
by the ethics committee of the University of Heidelberg
(registration number 442/2005).
2.2. Study Sample. The electronic patient records of 105,026
primary care patients across a three-year period (April 1,
2007–March 31, 2010) were screened in an anonymous
manner. Patients with PAD were identiﬁed using the Inter-
national Classiﬁcation of Disease (ICD-10) code I73.9. CVD
patients were selected from the ICD-10 codes I20 and I25.
This method allows extraction of all PAD/CVD patients
who exhibit ensured and coded diagnoses in their electronic
patients record. Thus not only patients who had become
conspicuous through their symptoms and were deﬁnitively
diagnostically clariﬁed were detected, but also those who
have become asymptomatic subsequent to PTA/PTCA treat-
ment. However, we were not able to extract, for example,
information about the number of therapeutic interventional
or surgical procedures and their possible medical success or
consequences. Asymptomatic patients, and thus the majority
of PAD patients, could not be identiﬁed because ABI
measurement was not available as a PAD selection criterion.
Furthermore, patients presenting with atypical claudication
symptoms, for example, patients with superimposing coin-
cident neuropathy or osteoarthrosis, could not be identiﬁed.
This is traced to a nonexistent ICPC code or ICD-10 code
for the Doppler sonographic ABI measurement. Subjects
presented coincidentally with PAD code and CVD code were
excluded from the analysis. Moreover, only patients with
continuous contact to their family practitioner and properly
documented prescriptions were included. In order to obtain
comparable cohorts, we identiﬁed determinants for PAD
on the basis of binary logistic regression. Based on these
variables,matchingwasperformedwiththePropensityScore
(PS) method proposed by Rosenbaum and Rubin [12]. The
package “Matching of R” (Version 2.12.0) [13]w a su s e d
for the matching procedure. For evaluation of the matching
results the “MatchBalance” function of this package was
applied, since this function not only examines diﬀerences of
means, but also accounts for potential diﬀerences across the
entire distribution [14].
Sociodemographic variables (e.g., education or profes-
sion) were not available for the analysis. The “chronic con-
ditions” were deﬁned on the basis of ICPC codes according
totheconceptofO’Halloranetal.[15]thatregardsdiagnoses
as well as chronic symptoms and complaints.
All prescriptions corresponding to the PAD code and
the CVD code were analysed by means of the Anatomical
Therapeutic Chemical Classiﬁcation (ATC). The ATC system
divides the drugs into diﬀerent groups according to the
organ or system on which they act and according to
their chemical, pharmacological, and therapeutic properties.
Drugs are classiﬁed in 14 main groups (ﬁrst level) and spread
outintotherapeutic/pharmacologicalsubgroupsdowntothe
plain chemical substances (ﬁfth level) [16].
2.3. Statistics. In order to assess potential diﬀerences in
pharmacotherapybetweenPADandCVDpatientsinmatters
of well-deﬁned ATC subgroups, contingency comparisons
were performed using Fisher’s Exact Test. A signiﬁcance level
of 0.05 was deﬁned for hypothesis testing. Statistical analyses
were performed with “R” (Version 2.12.0).
3. Results
479 PAD patients and 1,972 CVD patients met the inclu-
sion criteria. The matched-pair procedure resulted in 958
corresponding CVD patients, that is, a PAD/CVD patient
ratio of 1:2. Binary logistic regression deﬁned patients’
age, gender, practice setting, and type of health insurance
(statutory versus private) as signiﬁcant determinants for the
analysis (Table 1) .T h em a t c h i n gp r o c e d u r er e s u l t e di na n
exact match for patients’ gender and practice setting for the
entire PAD group. The percentage of patients with private
health insurance was slightly but not signiﬁcantly lower in
the PAD cohort (7.1% PAD versus 9.0% CVD). There was
no signiﬁcant diﬀerence in average age at the end of the
observation period for PAD patients and CVD patients.
The “MatchBalance” function indicated that patients’ age in
both cohorts was distributed very similarly. There was no
diﬀerence between PAD and CVD patients concerning the
numberof“chronicconditions”.Aswasexpected,thestudied
patient cohorts were of markedly older age compared to the
total register sample (Table 2).
Table 3 shows that the total number of prescribed
drugs did not diﬀer between the PAD and CVD cohorts.
However, compared to the PAD patients, the CVD patients
received signiﬁcantly more drugs of the ATC level 1 group
C “cardiovascular system”. The more detailed ATC level 2
subgroup analysis suggested that this distinction is primarily
based on higher prescription rates for cardiac therapy agents,
β-blockers, and lipid-lowering agents. In contrast, PAD
patients presented signiﬁcantly more frequent prescriptions
for antidiabetic agents than CVD patients, particularly more
insulin and analogues and more calcium channel blockers.
The analysis of ATC drug levels 4 and 5 showed that
the diﬀerence between prescriptions of lipid-lowering agents
is mainly caused by higher HMG-CoA reductase inhibitor
nominations among CVD patients, in particular simvastatin
prescriptions. The ATC groups level 5 of antithrombotic
agents suggested equal prescription rates for aspirin and
clopidogrel between the CVD and PAD cohorts. Remarkably,
no cilostazol prescriptions were registered.
4. Discussion
In the present study, we attempt to depict the secondary
medical prevention among symptomatic patients with PAD
compared to CVD patients in German primary care. The
analysis of the GP’s prescription dataset suggested no
substantial diﬀerence in the total number of prescribed
drugs between PAD and CVD patients. This concerned
all medications except cardiovascular drugs, which more
frequently emerged in the prescriptions for cardiac patients
than in those of patients with peripheral vascular disorder.
This distinction is based on signiﬁcantly more dispensationsInternational Journal of Vascular Medicine 3
Table 1: Study patient characteristics.
PAD patients CVD patients P-value
Number 479 958 n.s.
Age
mean (SD) 72.6 (12.0) 72.9 (11.2) n.s.
Gender
males (%) 56.4 56.4 n.s.
females (%) 43.6 43.6 n.s.
Number “chronic conditions”
mean (SD) 4.1 (3.7) 4.2 (3.6) n.s.
Number encounters (per mille) 38.8 (28.3) 37.2 (29.0) n.s.
Practice proﬁle‡ 100%
‡corresponding PAD patients and CAD patients were matched within the same practice setting without exception.
Table 2:PrevalenceofPADwithindiﬀerentagegroupsoftheentire
study population.
Age group (years) 3-year contact group PAD
n % n %
0–10 7700 7.33 0 0.00
11–20 10443 9.94 0 0.00
21–30 12930 12.31 1 0.21
31–40 12933 12.31 3 0.63
41–50 17533 16.69 15 3.13
51–60 13893 13.23 68 14.20
61–70 11588 11.03 125 26.10
71–80 10212 9.72 155 32.36
81–90 6379 6.07 98 20.46
>90 1415 1.35 14 2.92
Total 105026 100.0 479 100.0
of speciﬁc cardiac agents for CVD patients, for example,
glycosides, antiarrhythmics, or nitrates, and particularly on
more prescribed β-blockers. The latter disparity accords with
studies conducted in the U.S. and Europe, which reported
marked diﬀerences for treatment with β-blockers between
the two studied populations [1, 6, 17]. This may not only
be related to the fact that CVD management is mainly
inﬂuenced by specialists, whereas PAD is largely managed
in primary care. There is also an incomprehensible restraint
of some physicians to administer β-blockers among PAD
patients, although β-blocker therapy was proven as being
nondetrimental to walking capacity [18] and is even related
to a signiﬁcant independent decrease in new coronary events
[19].
Little is known about the secondary preventive eﬀects
of other classes of antihypertensive drugs in the presence
of PAD [20]. In our study, 67% of both the PAD and CVD
patients obtained ACE inhibitors/AT-II receptor antagonists.
Our data are consistent with results of other inpatient
and outpatient studies [6, 7, 9, 17]. Notably, PAD patients
received signiﬁcantly more calcium channel blockers than
patients with CVD, perhaps as a consequence of GPs’
contemplating the peripheral vasodilatation eﬀect of these
agents. The data of the German REACH study [6]d e m o n -
strated a similar but not signiﬁcantly higher administration
of calcium-antagonists in PAD patients than in patients with
CVD (31% versus 27%).
As an eﬀective secondary-preventive measure, the PAD
guidelines recommend lifelong treatment of symptomatic
patients with statins [21]. The 4S Study of 4,444 patients
with known cardiovascular disease revealed that use of sim-
vastatin reduced episodes of new or worsening intermittent
claudication [22]. Moreover, the Heart Protection Study
demonstrated that statins reduced coronary death in PAD
patients irrespective of their initial cholesterol value [23].
In our study, only half of the PAD patients received an
appropriate lipid-lowering therapy. In accordance with the
literature this conﬁrms an undertreatment of PAD patients
with lipid-lowering agents in primary care, in particular, in
view of the advanced stage of the disease [7, 9, 24].
Despite PAD guideline recommendations for secondary
prevention, the eﬀect of aspirin in this population is not
well established. A meta-analysis of eighteen prospective
randomized trials involving 5269 participants resulted in
a demand for additional randomized controlled trials of
aspirin therapy to establish thereal beneﬁtand bleeding risks
in PAD [25]. Nevertheless, in numerous more recent stud-
ies, patients with atherothrombotic diseases are univocally
considered as aspirin underused [1, 7, 17, 26]. However, the
ﬁndings of our study cannot contribute a substantial result
to this issue. The comparably low aspirin prescription rates
of 43% in both PAD and CVD cohorts do not reﬂect the
real intake of low-dose aspirin by these patients, because
in German pharmacies aspirin compounds are obtainable
as over-the-counter medication being even cheaper than
prescribed aspirin copayment.
The ﬁndings of our study suggest an inadequate preven-
tive medical therapy in patients with PAD in German family
practice settings as had already been demonstrated in other
studies [1–7, 17, 24, 25]. Taking into account that the study
sample consists of PAD patients suﬀering from an advanced
stage of the disease, an overestimation of the general treat-
ment prevalence in PAD/CVD patients can be assumed. The
real cardiovascular drug supply of patients with PAD would
probablybelessintensiveifasymptomaticPADpatientswere4 International Journal of Vascular Medicine
Table 3: Number of selected pharmacotherapeutical prescriptions in a 3-year study group of PAD and CVD patients by means of ATC
classiﬁcation.
PAD (n = 479) CVD (n = 958) P value
Total number, mean (SD) 46.9 ±39.94 2 .8 ±37.7n . s .
ATC groups level 1
A alimentary tract and metabolism 322 (67.2%) 618 (64.5%) n.s.
B blood and blood forming organs 318 (66.4%) 615 (64.2%) n.s.
C cardiovascular system 405 (84.6%) 849 (88.6%) <.05
ATC groups level 2
A 10 antidiabetic agents 135 (28.2%) 194 (20.3%) <.001
B 01 antithrombotic agents 303 (63.3%) 584 (61.0%) n.s.
C 01 cardiac therapy agents 101 (21.1%) 354 (37.0%) <.0001
C0 7β-blockers 240 (50.1%) 635 (66.2%) <.0001
C 08 calcium channel blockers 140 (29.2%) 233 (24.3%) <.05
C 09 renin-angiotensin system agents 322 (67.2%) 656 (68.5%) n.s.
C 10 antihyperlipidemics 241 (50.3%) 536 (55.9%) <.05
ATC groups level 3+4
A 10A insulins and analogues 60 (12.5%) 77 (8.0%) <.05
A 10B oral blood glucose lowering agents 96 (20.0%) 156 (16.3%) n.s.
B 01AA Vitamin K antagonists 56 (11.7%) 124 (12.9%) n.s.
B 01AB heparin and derivates 50 (10.4%) 97 (10.1%) n.s.
B 01AC platelet aggregation inhibitors 254 (53.0%) 481 (50.2%) n.s.
C 09AA ACE inhibitors, plain 198 (41.3%) 439 (45.8%) n.s.
C 10AA HMG CoA reductase inhibitors 222 (46.3%) 504 (52.6%) <.05
ATC groups level 5
B 01AC04 clopidogrel 101 (21.1%) 186 (19.4%) n.s.
B 01AC06 acetylsalicylic acid 206 (43.0%) 420 (43.8%) n.s.
B 01AC23 cilostazol 0 (0.0%) 0 (0.0%) n.s.
C 09AA05 ramipril 139 (29.0%) 310 (32.4%) n.s.
C 10AA01 simvastatin 195 (40.7%) 443 (46.2%) <.05
additionally included in the statistical analysis. The reason
for the underuse of preventive cardiovascular medication
in patients with atherosclerotic disease remains speculative.
Besidesadeﬁcientrealizationofguidelinerecommendations,
a general lacking awareness among physicians of the PAD
patients cardiovascular hazard could be supposed, tending to
result in neglect of appropriate medication [27, 28].
We are aware of the limitations inherent to any study
extracting data from electronic patient records. The main
weakness of our study is the data collection by means of
ICD/ICDC coded diagnoses which disregards asymptomatic
patients with PAD/CVD and is more selective with regard to
the advanced stages of the atherosclerotic disease. Further-
more, a potential selection bias must be admitted because
a GP’s participation in the CONTENT registry is voluntary
and not by random selection. In view of the considerable
number of participating practices and analyzed patients, it
can nevertheless be assumed that our study ﬁndings give
at least a realistic insight into the drug treatment of PAD
patients in primary care. We should also underline that
with the ATC classiﬁcation we only analysed plain chemical
substancesandnotcompoundmedicines,andforthisreason
a slight underestimation of true agent use cannot be ruled
out. Altogether, we believe the key information of our study
ﬁndings is not substantially aﬀected by these limitations,
especially as a possible bias involves a systematic error for
both the PAD and CVD cohorts.
5. Conclusion
The ﬁndings of the present study reﬂect an overall picture
of secondary prevention drug management in patients with
PAD in German primary care. In accordance with the
international literature, the treatment guidelines have not
been suﬃciently enough translated into family practice set-
tings. The analysed PAD patient sample was less intensively
treated with β-blockers, ACE inhibitors, and lipid-lowering
agents than comparable CVD patients. As a consequence,
serious considerations should be taken to implement the
PAD therapy guidelines recommendations more eﬀectively
in practice.
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